共 1199 条
[1]
Bianchini G(2022)Treatment landscape of triple-negative breast cancer - expanded options, evolving needs Nat Rev Clin Oncol 19 91-113
[2]
De Angelis C(2019)Genomic and Transcriptomic Landscape of Triple-Negative breast cancers: subtypes and treatment strategies Cancer Cell 35 428-440e425
[3]
Licata L(2021)Checkpoint inhibitor therapy for metastatic triple-negative breast cancer Cancer Metastasis Rev 40 537-47
[4]
Gianni L(2020)Unraveling triple-negative breast Cancer Tumor Microenvironment Heterogeneity: towards an Optimized Treatment Approach J Natl Cancer Inst 112 708-19
[5]
Jiang YZ(2020)A mir-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer Cell Death Dis 11 731-20
[6]
Ma D(2022)Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway Neoplasia 32 100821-306
[7]
Suo C(2020)Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer Nat Commun 11 2416-26
[8]
Shi J(2018)Collagen prolyl 4-hydroxylase 1 is essential for HIF-1alpha stabilization and TNBC chemoresistance Nat Commun 9 4456-18
[9]
Xue M(2021)Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy Br J Cancer 124 1110-17
[10]
Hu X(2023)Identification of INFG/STAT1/NOTCH3 as gamma-mangostin’s potential targets for overcoming doxorubicin resistance and reducing cancer-associated fibroblasts in triple-negative breast cancer Biomed Pharmacother 163 114800-8